Skip to content

20-185 - A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

Status: open

This project is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory track illness in infants. Pregnant women will be given a stabilized RSV prefusion F subunit vaccine or placebo during late 2nd trimester or early 3rd trimester of pregnancy. There will be infant follow-up for 24 months.

Prevent respiratory syncytial virus (RSV) disease by immunizing pregnant women

Contact Us


This study evaluates the use of Digoxin immune fab in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.


This trial is sponsored by Pfizer.

Providers Associated With This Trial

Sub Investigators

  • Tracy RothView Profile
    Tracy Y. Roth, M.D.Obstetrician/GynecologistResidency Program Director for Obstetrics and Gynecology; Assistant Professor of Obstetrics and Gynecology; Focused Practice Designation in Pediatric and Adolescent Gynecology
  • Benjamin EstradaView Profile
    Benjamin Estrada, M.D.Pediatric Infectious DiseaseAssistant Dean for Educational Strategies and Faculty Development; Professor and Vice Chair of Pediatrics
  • Dr Holliday new head shotView Profile
    Nicolette P. Holliday, M.D., F.A.C.O.G.Obstetrician/GynecologistAssociate Professor of Obstetrics and Gynecology/Focused Practice Designation in Pediatric and Adolescent Gynecology
This link will open in a new tab or window.